The effects of PACAP and PACAP antagonist on the neurobehavioral development of newborn rats

Recent studies show that pituitary adenylate cyclase activating polypeptide (PACAP) plays an important role in the development of the nervous system. The aim of the present study was to investigate the effects of PACAP38 and the PACAP antagonist PACAP6-38 on the development of neonatal behavior in rats. Pups were treated subcutaneously until day 14, a period during which the blood–brain barrier is not yet complete. Rats were tested daily for the appearance of physical features, sensory and motor neurological signs, and for exploratory behavior on days 14 and 21. Facial development and most neurological signs were accelerated by PACAP treatment, while anti-PACAP retarded ear unfolding, eye opening, hindlimb placing and righting reflex. PACAP-treated animals also showed altered behavior in the open-field, in particular at 3 weeks of age. The number of areas entered and rearings were much higher than in the vehicle-treated group, and they spent less time along the walls and in corners. Anti-PACAP had little effect in the exploratory behavior of the pups. In summary, these data provide additional evidence for the neurotrophic effects of both endogenously present and exogenously administered PACAP-38.